| Identification | Back Directory | [Name]
(S)-Di-Tert-Butyl 2-(3-((S)-6-Amino-1-(Tert-Butoxy)-1-Oxohexan-2-Yl)Ureido)Pentanedioate | [CAS]
1025796-31-9 | [Synonyms]
min. 96%, min
tert-Butyl-DCL (PSMA inhibitor)
(S)-Di-Tert-Butyl 2-(3-((S)-6-Amino-1-(Tert-Butoxy)-1-Oxohexan-2-Yl)Ureido)Pentanedioate
(S)-Di-Tert-Butyl 2-(3-((S)-6-Amino-1-(Tert-Butoxy)-1-Oxohexan-2-Yl)Ureido)Pentanedioate(WXC02272)
ditert-butyl (2S)-2-[[(2S)-6-amino-1-[(2-methylpropan-2-yl)oxy]-1-oxohexan-2-yl]carbamoylamino]pentanedioate
(S)?-?DI-?TERT-?BUTYL 2-?(3-?((S)?-?6-?AMINO-?1-?(TERT-?BUTOXY)?-?1-?OXOHEXAN-?2-?YL)?UREIDO)?PENTANEDIOATE; MIN. 96?%, MIN
L-Glutamic acid, N-[[[(1S)-5-amino-1-[(1,1-dimethylethoxy)carbonyl]pentyl]amino]carbonyl]-, 1,5-bis(1,1-dimethylethyl) ester | [Molecular Formula]
C24H45N3O7 | [MDL Number]
MFCD28898592 | [MOL File]
1025796-31-9.mol | [Molecular Weight]
487.63 |
| Chemical Properties | Back Directory | [Boiling point ]
596.6±50.0 °C(Predicted) | [density ]
1.072±0.06 g/cm3(Predicted) | [solubility ]
Water: Soluble | [form ]
Solid-Liquid Mixture | [pka]
12.09±0.46(Predicted) | [color ]
Colorless to off-white | [InChIKey]
IXWXFSGSTGXUFO-IRXDYDNUSA-N | [SMILES]
C(OC(C)(C)C)(=O)[C@H](CCC(OC(C)(C)C)=O)NC(N[C@H](C(OC(C)(C)C)=O)CCCCN)=O |
| Hazard Information | Back Directory | [Chemical Properties]
Appearance: White powder
Purity (HPLC): ≥98.0%
Acetate content ≤12.0%
Water content ≤8.0%
Peptide content ≥80.0%
Endotoxin ≤50EU/mg
Amino acid composition analysis ≤±10% | [Uses]
(S)-Di-tert-butyl 2-(3-((S)-6-Amino-1-(tert-butoxy)-1-oxohexan-2-yl)ureido)pentanedioate is used as a reactant in the synthesis of novel multivalent fluorescent inhibitors with high affinity to prostate cancer. | [References]
[1] JOANA F. SANTOS, ANTÓNIO PAULO* Synthesis and Preclinical Evaluation of PSMA-Targeted 111In-Radioconjugates Containing a Mitochondria-Tropic Triphenylphosphonium Carrier[J]. Molecular Pharmaceutics, 2023, 21 1: 216-233. DOI: 10.1021/acs.molpharmaceut.3c00787 |
|
|